<DOC>
	<DOC>NCT00097955</DOC>
	<brief_summary>Study of the efficacy and safety of aliskiren when added to losartan and optimal antihypertensive therapy in patients with hypertension, type 2 diabetes, and kidney disorders to monitor improvement in any of these conditions.</brief_summary>
	<brief_title>Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and Proteinuria</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Proteinuria</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Antihypertensive Agents</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<criteria>Hypertension Elevated urinary protein levels Confirmed type 2 diabetes Certain diseases Uncontrolled diabetes Type 1 diabetes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>diabetes</keyword>
	<keyword>nephropathy</keyword>
	<keyword>hypertension</keyword>
	<keyword>aliskiren</keyword>
	<keyword>losartan</keyword>
</DOC>